Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8545242 | PMC |
| http://dx.doi.org/10.1161/ATVBAHA.121.316808 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Combinatorial functionomics identifies HDAC6-dependent molecular vulnerability of radioresistant head and neck cancer.
Exp Hematol Oncol
January 2025
Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.
Background: Radiotherapy is the primary treatment modality for most head and neck cancers (HNCs). Despite the addition of chemotherapy to radiotherapy to enhance its tumoricidal effects, almost a third of HNC patients suffer from locoregional relapses. Salvage therapy options for such recurrences are limited and often suboptimal, partly owing to divergent tumor and microenvironmental factors underpinning radioresistance.
View Article and Find Full Text PDFAnemia of Inflammation is a prevalent co-morbidity in patients with chronic inflammatory disorders. Inflammation causes hypoferremia and iron-restricted erythropoiesis by limiting Ferroportin (FPN)-mediated iron export from macrophages that recycle senescent erythrocytes. Macrophage cell surface expression of FPN is reduced by hepcidin-induced degradation and/or by repression of FPN (Slc40a1) transcription via cytokine and Toll-like receptor (TLR) stimulation.
View Article and Find Full Text PDFMulti-Target Inhibitor CUDC-101 Impairs DNA Damage Repair and Enhances Radiation Response in Triple-Negative Breast Cell Line.
Pharmaceuticals (Basel)
November 2024
Department of Physiology, School of Medicine, Faculty of Health Sciences, University of Pretoria, Pretoria 0028, South Africa.
Article Synopsis
- - The study investigates CUDC-101, a multitarget inhibitor, and its ability to improve radiation response in breast cancer when combined with proton and X-ray irradiation, with a focus on triple-negative breast cancer cell lines.
- - Results showed that CUDC-101 enhanced sensitivity to radiation, increased apoptosis, and caused G2/M cell cycle arrest, particularly in the aggressive MDA-MB-231 cell line.
- - The findings suggest that CUDC-101 could be an effective option for treating triple-negative breast cancer, either on its own or alongside radiation therapies.
Induction of neuronal differentiation in glioma cells by histone deacetylase inhibitors based on Connectivity Map discovery.
Anticancer Drugs
February 2025
Department of Pharmacy, Zhongshan Hospital (Xiamen), Fudan University.
Neuron conversion leads to proliferation inhibition of glioma cells and may be an effective strategy to combat glioma and prevent recurrence. In this study, drug repositioning based on Connectivity Map (CMap) was conducted to discover drugs that could induce the differentiation of glioma cells into neuron-like cells, complemented by in vitro experimental validation. Downregulated neuronal genes in glioma were identified by the Human Protein Atlas database and the GeneCards database, and enrichment analysis and Gene Expression Profiling Interactive Analysis (GEPIA) were performed to ensure their reliability before they were uploaded to CMap for drug screening.
View Article and Find Full Text PDFPanobinostat Synergizes with Chemotherapeutic Agents and Improves Efficacy of Standard-of-Care Chemotherapy Combinations in Ewing Sarcoma Cells.
Cancers (Basel)
October 2024
Levine Children's Hospital, Charlotte, NC 28203, USA.
The survival rate of patients with Ewing sarcoma (EWS) has seen very little improvement over the past several decades and remains dismal for those with recurrent or metastatic disease. HDAC2, ALK, JAK1, and CDK4 were identified as potential targets using RNA sequencing performed on EWS patient tumors with the bioinformatic analysis of gene expression. The pan-HDAC inhibitor Panobinostat was cytotoxic to all the Ewing sarcoma cell lines tested.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!